Tacrolimus ointment 0.1% for the treatment of peristomal skin disease: 3 Case reports

Cutis

Volumn 78, Issue 4, 2006, Pages 258-260

  Wells, Gregory L ^a   Brown, Joanne ^b   Manganiello, Wendy D ^b   Chapman, M Shane ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

AGED; ARTICLE; BLADDER TUMOR; CASE REPORT; COLON TUMOR; DERMATITIS; FEMALE; HUMAN; MALE; OINTMENT; STOMA; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; DERMATITIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; STOMAS; TACROLIMUS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33750860535     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Rothstein MS. Dermatologic considerations of stoma care. J Am Acad Dermatol. 1986;15:411-432.
2. Rothstein MS. Management of stomal wounds. Clin Dermatol. 1994;12:81-88.
3. Lyon CC, Smith AJ, Griffiths CE, et al. The spectrum of skin disorders in abdominal stoma patients. Br J Dermatol. 2000;143:1248-1260.
4. Lyon CC, Smith AJ, Griffiths CE, et al. Peristomal dermatoses: a novel indication for topical steroid lotions. J Am Acad Dermatol. 2000;43:679-682.
5. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136-142.
6. Clipstone NA, Crabtree GR. Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. Ann N Y Acad Sci. 1993;696:20-30.
7. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992;357:695-697.
8. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997;337:816-821.
9. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol. 1998;38:69-76.
10. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001;44(suppl 1):S28-S38.
11. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44(suppl 1):S47-S57.
12. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44(suppl 1):S58-S64.
13. Lauerma AI, Maibach HI. Topical FK506 - clinical potential or laboratory curiosity? Dermatology. 1994;188:173-176.
14. Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 2000;141;103-107.
15. Richter-Hintz D, Schuppe H-C, Homey B, et al. Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum. J Am Acad Dermatol. 2000;42:304-305.
16. Schuppe HC, Homey B, Assmann T, et al. Topical tacrolimus for pyoderma gangrenosum [letter]. Lancet. 1998;351:832.
17. Jolles S, Niclasse S, Benson E. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol. 1998;140;564-565.
18. Valencia IC, Kerdel FA. Topical glucocorticoids. In: Freedberg IM, Eisen AZ, Wolff K, et al, eds. Fitzpatrick's Dermatology in General Medicine. 6th ed. New York, NY: McGraw-Hill; 2003:2324-2328.